Last Updated: 19 April 2026
Hims & Hers Health (NYSE: HIMS) is the largest direct-to-consumer telehealth platform in the US, with 2.51 million subscribers and $2.35 billion in FY2025 revenue. The business model — subscription telehealth with vertically integrated compounding pharmacies — has been shaken in the last 90 days by the FDA's tightening stance on compounded GLP-1 medicines, a short-lived patent lawsuit from Novo Nordisk, and a DOJ referral. It has also been boosted by a mid-March settlement that turned Novo from plaintiff into distribution partner, and a surprise 16 April announcement from RFK Jr. that the FDA will review removing 12 peptides from compounding restrictions. This report walks through the numbers, the moat, the risks and every material development in the last six months.
1. Company Snapshot
| Item | Detail |
|---|---|
| Full name | Hims & Hers Health, Inc. |
| Ticker | NYSE: HIMS |
| Sector / Industry | Healthcare / Telehealth & Digital Health |
| Founded | 2017 (Public via SPAC, January 2021) |
| Headquarters | San Francisco, California, USA |
| CEO | Andrew Dudum (Co-Founder) |
| Market cap (19 April 2026) | ~$6.57 billion |
| Share price | ~$28.66 |
| Revenue (FY2025) | $2,347.6 million (+59% YoY) |
| Net income (FY2025) | $128.4 million |
| Employees | ~5,000+ |
| Exchange | NYSE (primary) |
| Website | hims.com |
2. Bull Case vs Bear Case
Bull Case
- Scale and growth. Largest US D2C telehealth platform, 2.51m subscribers (+13% YoY), $2.35bn FY25 revenue (+59% YoY). Multi-condition subscribers grew 80% YoY and now exceed 20% of the base.
- Vertical integration. Owns MedisourceRx (503B compounding), Trybe Labs (at-home testing), peptide manufacturing (former CS Bio assets). Supply chain control enables higher gross margins than a pure referral model.
- Novo Nordisk partnership. March 2026 settlement made Hims a preferred D2C distributor of branded Wegovy and Ozempic; CEO Dudum has publicly stated the company is "on track to deliver over 100,000 Wegovy prescriptions per month."
- Peptide optionality. On 16 April 2026, HHS/FDA announced a July 2026 advisory review of removing 12 peptides (BPC-157, TB-500, semax, epitalon, others) from Category 2 restrictions. If reclassified, Hims can legally compound them — repurposing existing manufacturing capacity into new high-margin categories.
- Profitable with growing international footprint. FY25 adjusted EBITDA $318m (13.5% margin). Acquisitions of ZAVA (UK, Germany, France, Ireland) and Livewell (Canada) drove international revenue +400% to ~$134m.
Bear Case
- FDA compounding crackdown. May 2025 ended the semaglutide shortage exemption. In February 2026 the FDA forced Hims to withdraw its $49 compounded oral semaglutide pill within 48 hours and HHS referred the company to the DOJ. Compounded margins are structurally at risk.
- Gross margin compression. Gross margin fell from 79% in FY24 to 74% in FY25. The Novo partnership distributes branded drugs at ~25–35% gross margin vs 60–70% on compounded alternatives. Q1 2026 guidance carries a ~$65m weight loss timing headwind.
- Active DOJ and SEC attention. DOJ referral remains open; SEC probing disclosures. Outcomes unknown; legal costs and reputational damage are live.
- Subscriber growth decelerating. 13% subscriber growth in 2025 is well below broader telehealth (20–30% CAGR). Weight loss economics are being reset.
- Leverage up sharply. Total debt rose to ~$971m in 2025 (from ~$150m) after a $1.0bn convertible senior note issuance in May 2025. Debt-to-equity ~1.8x; dilution risk on the convert is real.
3. What Does This Company Actually Do?
Hims & Hers runs a direct-to-consumer telehealth subscription platform. A customer completes an online intake, is matched with a licensed clinician, gets a prescription (where appropriate), and receives the medication on recurring delivery. Over time the company has built — or bought — the pieces of the stack, including the compounding pharmacy that makes many of the medicines.
| Revenue stream (FY25) | Approx share | Detail |
|---|---|---|
| Online Revenue | ~98.4% (~$2,310m) | D2C subscriptions on the Hims and Hers platforms |
| Wholesale Revenue | ~1.6% (~$38m) | B2B health plan and pharmacy partnerships |
| International Revenue (included above) | ~$134m | +400% YoY post ZAVA and Livewell acquisitions |
By product category the mix is roughly weight loss ~31%, sexual health (Hims) ~30%, women's health (Hers) ~30%, mental health, dermatology and hormonal health (new low-T and menopause lines launched in 2025). Customers are almost entirely B2C consumers in the US, Canada, UK, Germany, France and Ireland.
4. The Business Model
Revenue is recurring subscription, and the moat sits in three places: (1) brand and scale — Hims/Hers is one of the most recognised consumer health brands in the US, with 2.5m paying subscribers; (2) vertical integration — owning the compounding pharmacy (MedisourceRx 503B), peptide manufacturing (former CS Bio facility) and at-home lab testing (Trybe Labs); (3) data and personalization — 50% YoY growth in personalized-plan subscribers, with multi-condition users (80% YoY growth) generating substantially higher lifetime value.
| Margin metric | FY2025 | FY2024 |
|---|---|---|
| Gross margin | 74% | 79% |
| Operating margin | 4.5% | 4.2% |
| Net profit margin | 5.5% | 8.5% |
| Adjusted EBITDA margin | 13.5% | ~10.8% |
Subsidy / regulatory credit dependency. Hims does not receive direct government subsidies. However, its compounded-drug margin structure depends on regulatory permission to compound medicines under FDA rules (503A and 503B). When the FDA declared the semaglutide shortage over in May 2025 it removed the legal basis for mass-market compounding of semaglutide; this is functionally a negative regulatory-credit event. The reverse — de-restriction of 12 peptides under review in July 2026 — would be a positive one. This regulatory exposure is the single most important thing to understand about the business model.
5. Financial Health
| Year | Revenue | Net income | YoY revenue |
|---|---|---|---|
| 2020 | $52.7m | -$13.4m | — |
| 2021 | $152.4m | -$29.9m | +189% |
| 2022 | $594.9m | -$22.4m | +290% |
| 2023 | $926.3m | $51.2m | +56% |
| 2024 | $1,476.5m | $126.0m | +59% |
| 2025 | $2,347.6m | $128.4m | +59% |
| Cash & balance sheet (year-end 2025) | Amount |
|---|---|
| Operating cash flow (FY25) | $300.0m |
| Free cash flow (FY25) | $57.4m |
| Capex (FY25) | ~$242.6m (+232% YoY) |
| Cash & equivalents | $578m |
| Short-term investments | $51.7m |
| Long-term investments | $351m |
| Total debt | $971m (incl. $1.0bn convertible notes due 2030) |
| Net debt | ~$393m |
| Principal liquidity | ~$929m |
FCF fell year-over-year despite higher operating cash flow, because capex tripled. No dividend. Share count has grown with equity comp and the May 2025 convertible note.
6. Valuation & Market Data
Figures below sourced from public filings and market data providers as of 19 April 2026. Intraday numbers change — use the ChartsView live charts for the current price.
| Metric | Value |
|---|---|
| Share price | ~$28.66 |
| Market cap | ~$6.57bn |
| Enterprise value | ~$6.37bn |
| P/E (trailing) | ~30–56x (varies by source) |
| P/E (forward) | ~52x |
| P/S (trailing) | ~2.8x |
| EV/EBITDA (on FY25 adj EBITDA) | ~40x |
| EV/FCF | ~96x (capex distorted) |
| 52-week high | $70.43 (19 Feb 2025) |
| 52-week low | $13.74 (27 Feb 2026) |
| Short interest (shares) | 71.36m |
| Short interest (% of float) | ~31.3% |
| Days to cover | ~2.5 |
| Short interest report date | 31 March 2026 |
Short interest is very high — over 30% of float — though days-to-cover is only a couple of days given the stock's high daily turnover.
7. What Are They Building / What's Coming?
GLP-1 — from compounding to distribution
After the FDA declared the semaglutide shortage over in May 2025 and forced a pullback of Hims' compounded oral semaglutide pill in February 2026, the company settled the Novo Nordisk patent lawsuit on 9 March 2026. Under the settlement, Hims distributes branded Wegovy and Ozempic at comparable pricing to other telehealth platforms. CEO Dudum stated publicly the company is "on track to deliver over 100,000 Wegovy prescriptions per month." Hims has ceased mass-marketing of compounded GLP-1 alternatives.
Peptide optionality (catalyst: 23–24 July 2026)
On 16 April 2026 HHS Secretary Robert F. Kennedy Jr. announced the FDA will convene a Pharmacy Compounding Advisory Committee on 23–24 July 2026 to review removing 12 peptides — including BPC-157, KPV, TB-500, MOTs-C, semax and epitalon — from Category 2 restrictions. If reclassified, Hims could compound and distribute them at scale. The stock rose 13.7% on the day of the announcement.
New categories launched 2025–2026
- Low testosterone. Compounded enclomiphene + tadalafil launched Q3 2025; exclusive partnership with Marius Pharmaceuticals for branded oral testosterone (KYZATREX) in 2026.
- Menopause / perimenopause. Hers specialty launched Q4 2025, with a stated target of $1bn of Hers revenue in 2026 (vs ~$700m in 2025).
- At-home diagnostics. Trybe Labs (acquired Feb 2025) integrating through 2026.
International
ZAVA (UK, Germany, France, Ireland — announced June 2025) and Livewell (Canada) added a combined ~1.3m European customers; international revenue grew ~400% YoY to ~$134m in 2025.
Management guidance (from the 23 February 2026 earnings call)
- Full year 2026 revenue $2.7–2.9bn (mid-point +19% YoY)
- Adjusted EBITDA $300–375m
- Q1 2026 revenue $600–625m; Adj EBITDA $35–55m — includes a ~$65m timing drag from weight-loss shipping cadence changes plus Super Bowl ad spend
8. Competitive Landscape
| Competitor | Position | Notes |
|---|---|---|
| Ro Pharmacy | Private D2C telehealth | Aggressive unit economics; similar multi-category playbook |
| LifeMD (LFMD) | Public D2C telehealth | ~500k subscribers; had a Novo Nordisk partnership that was scaled back in 2025 |
| Teladoc (TDOC) | B2B / enterprise telehealth | Different customer mix; less direct D2C competitor |
| Novo Nordisk | Branded GLP-1 | Now Hims' partner on Wegovy/Ozempic distribution |
| Eli Lilly | Branded tirzepatide | Zepbound/Mounjaro, not on the Hims platform as of April 2026 |
| CVS / Walgreens / Amazon Pharmacy | Retail pharmacy + telehealth | Growing digital-prescription capabilities |
Policy impact analysis. The FDA's May 2025 end of the semaglutide shortage was a symmetric shock — it hit Hims, Ro, LifeMD and independent compounders. Hims has the deepest compounding infrastructure (MedisourceRx, peptide facility) and the biggest brand, but it also has the most to lose by unit volume in weight loss. Novo and Lilly benefited: branded-only distribution post-shortage is worth more. If the July 2026 peptide advisory goes Hims' way, it would reopen a compounding edge that's hard to replicate quickly — favouring the player with owned 503B capacity.
9. Leadership and Ownership
Andrew Dudum co-founded Hims in 2017 and has been CEO since. Background: Wharton, Atomic Labs, early-stage consumer investor. Hilary Coles co-founded the business and leads the Hers brand. Yemi Okupe is CFO, with prior finance roles at Uber, eBay, PayPal and Google. Nader Kabbani was appointed COO in May 2025.
Ownership. Institutional ownership is approximately 73%. BlackRock holds ~11% and Vanguard ~8.6%. Insider ownership by the executive team is in the low single digits.
Recent insider transactions
| Name | Date | Type | Shares | Plan type | Notes |
|---|---|---|---|---|---|
| Andrew Dudum (CEO) | 9 April 2026 | Disposition — gift | 422,933 (×2 gifts = 845,866 total) | Non-sale (gift to trusts) | Estate/trust planning; direct holdings afterwards 887,684 shares |
No open-market discretionary CEO buying has been reported in 2026 to date. The April 9 activity is a gift to trusts (Form 4), not market selling. This is important context: the stock decline from $70 to $14 and back to $28 over 12 months has not been met with visible insider accumulation.
10. Risks and Challenges
- Regulatory / compounding risk. The FDA has active enforcement momentum on mass-marketed compounded GLP-1s. Extending similar actions to testosterone or dermatology compounds would hit margins hard.
- DOJ referral & SEC probe. HHS General Counsel referred Hims to DOJ in February 2026 over the semaglutide pill marketing. An SEC inquiry into disclosures is also reported. Both are open as of 19 April 2026.
- Mix shift on GLP-1. Shifting from ~60–70% gross margin compounded product to ~25–35% branded distribution structurally compresses category gross profit.
- Subscriber growth deceleration. 13% YoY below peer telehealth CAGR.
- Litigation risk. The Novo settlement reserves the right to refile. Other branded manufacturers may litigate.
- Capital structure. $1.0bn convert due 2030; debt-to-equity ~1.8x; dilution risk if the stock recovers to the conversion trigger.
- Key-person risk. Dudum is the face of the company and drives much of the brand messaging.
- Reputational risk. A regulatory enforcement headline cycle weighs on B2C trust in ways that don't show up in quarterly numbers until later.
11. Recent Developments
Last 48 hours
- 17–18 April 2026: Trading around $28 after the 16 April surge on the FDA/HHS peptide review announcement.
- 16 April 2026: HHS Secretary RFK Jr. announces FDA will review de-restriction of 12 peptides; advisory committee meetings scheduled 23–24 July 2026. HIMS closes +13.7%. Bank of America's price target raised to $25 (from $21) — note, we do not use analyst targets in our reports, this is noted only as a factual market event.
Previous 6 months
- 9 March 2026: Novo Nordisk drops patent lawsuit; Hims becomes a preferred D2C distributor of branded Wegovy/Ozempic. Dudum publicly cites 100,000 Wegovy prescriptions per month trajectory.
- 23 February 2026: Q4 / FY2025 earnings — revenue $2.348bn (+59% YoY), adjusted EBITDA $318m, 2.51m subscribers. FY26 guidance set at $2.7–2.9bn revenue and $300–375m adj EBITDA.
- 9 February 2026: Novo Nordisk sues Hims for patent infringement on compounded semaglutide.
- 7 February 2026: Hims withdraws its $49 compounded oral semaglutide pill within 48 hours of its launch.
- 6 February 2026: FDA announces intent to restrict GLP-1 APIs in mass-marketed compounded products; HHS General Counsel refers Hims to DOJ.
- 5 February 2026: Hims launches the $49 compounded oral semaglutide pill.
- Q4 2025: Hers menopause / perimenopause specialty launched; menopause is a stated $1bn 2026 revenue target.
- Q3 2025: Compounded enclomiphene + tadalafil launch; low-testosterone category opens.
- June 2025: ZAVA European acquisition announced (UK, Germany, France, Ireland); Livewell Canada completed later in 2025.
- May 2025: $1.0bn convertible senior notes due 2030 issued. FDA declares semaglutide shortage over — ends legal basis for mass-market semaglutide compounding.
- February 2025: Trybe Labs acquisition (at-home lab testing); peptide manufacturing facility acquired from former CS Bio assets.
12. Key Dates Coming Up
- 11 May 2026 — Q1 2026 earnings release (after close). First post-crisis print; watch Q1 revenue vs $600–625m guide.
- 23–24 July 2026 — FDA Pharmacy Compounding Advisory Committee on peptide Category 2 review. Largest binary catalyst.
- Early August 2026 — Q2 2026 earnings (expected). First full quarter of Novo Wegovy distribution.
- Early November 2026 — Q3 2026 earnings (expected).
Follow our economic calendar for scheduled earnings and macro events, and discuss trade ideas on the ChartsView forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.